SCHEDULE 13G/A 0001193125-21-192976 0001802528 XXXXXXXX LIVE 7 Common Stock, par value $0.001 per share 10/14/2025 0001454789 Astria Therapeutics, Inc. 04635X102 22 Boston Wharf Road, 10th Floor Boston MA 02210 Rule 13d-1(c) Fairmount Funds Management LLC DE 0.00 2377049.00 0.00 2377049.00 2377049.00 N 4.0 IA The shares reported herein for the Reporting Person represent (i) 650,000 shares of the Issuer's Common Stock Fairmount Healthcare Fund II LP ("Fund II") has the right to acquire through the exercise of 650,000 pre-funded warrants ("Pre-Funded Warrants"), and (ii) 1,727,049 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 1,727,049 common warrants ("Warrants"). Row 13 is based upon 58,811,943 shares of the Issuer's Common Stock outstanding as of October 14, 2025, consisting of (i) 56,434,894 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) 650,000 shares of Common Stock underlying the Pre-Funded Warrants and (iii) 1,727,049 shares of Common Stock underlying the Warrants owned by Fund II. Fairmount Healthcare Fund II GP LLC DE 0.00 2377049.00 0.00 2377049.00 2377049.00 N 4.0 OO The shares reported herein for the Reporting Person represent (i) 650,000 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 650,000 Pre-Funded Warrants, and (ii) 1,727,049 shares of the Issuer's Common Stock Fund II has the right to acquire through the exercise of 1,727,049 Warrants. Row 13 is based upon 58,811,943 shares of the Issuer's Common Stock outstanding as of October 14, 2025, consisting of (i) 56,434,894 shares of Common Stock outstanding as of July 31, 2025, as reported in the Company's most recent Quarterly Report on Form 10-Q, (ii) 650,000 shares of Common Stock underlying the Pre-Funded Warrants and (iii) 1,727,049 shares of Common Stock underlying the Warrants owned by Fund II. Astria Therapeutics, Inc. 22 Boston Wharf Road, 10th Floor Boston, MA, 02210 This Amendment No. 7 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on December 31, 2021, Amendment No. 1 thereto filed on September 22, 2021, Amendment No. 2 thereto filed on June 17, 2021, Amendment No. 3 thereto filed on February 14, 2023, Amendment No. 4 thereto filed on February 14, 2024, Amendment No. 5 thereto filed on November 14, 2024 and Amendment No. 6 thereto filed on February 14, 2025. (A) Fairmount Funds Management LLC (B) Fairmount Healthcare Fund II GP LLC (A) 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428 (B) 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428 (A) Delaware (B) Delaware Y As of October 14, 2025, Fund II holds (i) 650,000 Pre-Funded Warrants with the right to acquire 650,000 shares of Common Stock and (ii) 1,727,049 common warrants ("Warrants", with the right to acquire 1,727,049 shares of Common Stock at an exercise price of $8.025 per share). Pursuant to the terms of the Pre-funded Warrants and the Warrants, the Reporting Person's beneficial ownership limitation is currently 9.99% (the "Beneficial Ownership Limitation"), which prevents the Reporting Persons from exercising the Pre-funded Warrants or Warrants if, after giving effect to such exercise, the Reporting Persons, together with their affiliates, would beneficially own more than 9.99% of the Issuer's outstanding shares of Common Stock. See the response(s) to Item 11 on the attached cover page(s). See the response(s) to Item 5 on the attached cover page(s). See the response(s) to Item 6 on the attached cover page(s). See the response(s) to Item 7 on the attached cover page(s). See the response(s) to Item 8 on the attached cover page(s). N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Fairmount Funds Management LLC /s/ Peter Harwin 10/15/2025 /s/ Tomas Kiselak 10/15/2025 Fairmount Healthcare Fund II GP LLC /s/ Peter Harwin 10/15/2025 /s/ Tomas Kiselak 10/15/2025